NCT02167139View on ClinicalTrials.gov

A Study Comparing SB5 to Humira® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy

PHASE3CompletedINTERVENTIONAL

Enrollment

544

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

April 30, 2015

Study Completion Date

October 31, 2015

Conditions

Rheumatoid Arthritis

Interventions

DRUG

Humira (adalimumab)

DRUG

SB5 (proposed biosimilar to adalimumab)

Trial Locations (2)

Unknown

Investigational Site, Kaunas

Investigational site, Katowice

All Listed Sponsors

lead

Samsung Bioepis Co., Ltd.

INDUSTRY

NCT02167139 - A Study Comparing SB5 to Humira® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy | Biotech Hunter | Biotech Hunter